Clinical Utility of Tumor Next-Generation Sequencing Panel Testing to Inform Treatment Decisions for Patients With Advanced Solid Tumors in a Tertiary Care Center.

Lucia BogdanRamy R SalehLisa AverySamanta Del RossiCeleste Yu Philippe L Bedard

Published in: JCO precision oncology (2024)

OCTANE testing led to a change in drug treatment in 15.7% of patients, supporting the clinical utility of NGS panel testing for patients with advanced solid tumors.

Keyphrases

tertiary care
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
emergency department
prognostic factors
combination therapy
copy number
patient reported outcomes
drug induced